Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Search
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Breakthrough in Artificial Intelligence ChatGPT
Is ChatGPT the AI revolution we were waiting for or only media hype? Experts from Boehringer Ingelheim take a close look.
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
collaboration criving innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Kazakhstan
Kazakhstan
View from Both Sides of the Table
Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
Boehringer Ingelheim Second Transforming Science Day
World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Boehringer Ingelheim appointment to Board Managing Directors
Boehringer Ingelheim announces appointments to Board of Managing Directors
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
Boehringer expands cancer research at Vienna site
Boehringer Ingelheim expands cancer research at its Vienna site
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
Animal Health partnering interests
Animal Health partnering interests
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
LastMile increases access to veterinary care in Africa
Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
Brand of the Year Frontline pet parasiticides
FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
SENVELGO Best New Product Companion Animals award
SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
digital_leader_award_2020
Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development